

New specialty pharmacy medical step therapy requirements

Effective August 1, 2020, the following Part B medications from the current *Clinical Utilization Management (UM) Guidelines* will be included in our medical step therapy precertification review process. Step therapy review will apply upon precertification initiation, in addition to the current medical necessity review (as is current procedure). Step therapy will not apply for members who are actively receiving medications listed below.

Clinical UM Guidelines are publicly available on the provider website. Visit the [Clinical Criteria](#) page to search for specific criteria.

Clinical UM Guidelines	Preferred drug(s)	Non-preferred drug(s)
ING-CC-0072	Avastin (C9257*, J3490* <i>for ophthalmic conditions only</i> , J3590* <i>for ophthalmic conditions only</i> , J7999* <i>for ophthalmic conditions only</i> J9035 <i>for ophthalmic conditions only</i>) Mvasi (Q5107 <i>for ophthalmic conditions only</i>) Zirabev (Q5118 <i>for ophthalmic conditions only</i>) Eylea (J0178)	<i>Including but not limited to:</i> Lucentis (J2778) Beovu (J0179) Macugen (J2503)

* C9257 and not otherwise classified codes used for ophthalmic conditions (J3490, J3590, J7999) will continue to be excluded from the Part B precertification requirement.